To quantify the risk of skin reactions to antibacterial drugs under everyday circumstances in a large population with automated data from general practitioners (GP).
A retrospective cohort study in a dynamic population.
Data came from the Integrated Primary Care Information (IPCI) database.
The IPCI database consists of all data on consultations, morbidity, and prescriptions and other interventions, as registered by the GP in a source population of approximately 150,000 persons.
The study period started on April 1,1994, and ended on September 30,1995.
All patients who were treated with an antibacterial drug were enrolled on the first day of starting treatment until the end of the study period or until the occurrence of one or more of the following diagnoses within the risk period : allergic reaction, rash, erythema, pruritus and urticaria, or a notification of a skin reaction in the free text.
Subsequently, patient profiles were assessed by two authors who were blinded to exposure.
The risk period was defined as the legend duration of the antibacterial drug plus 14 days to control for carry-over of drug effects and delay in patient presentation.
Age, gender, and comedication were examined as potential confounders.
In the study period 13,679 patients received 19,961 prescriptions of an antibacterial drug.
It concerned 5330 men (39.0%) and 8349 (61.0%) women with a mean age of 41 and 42 years, respectively. (...)
Mots-clés Pascal : Antibactérien, Antiinfectieux, Allergie, Peau, Pratique professionnelle, Médecin généraliste, Epidémiologie, Toxicité, Homme, Base donnée, Pharmacovigilance, Pays Bas, Europe, Immunopathologie, Peau pathologie
Mots-clés Pascal anglais : Antibacterial agent, Antiinfectious, Allergy, Skin, Professional practice, General practitioner, Epidemiology, Toxicity, Human, Database, Pharmacovigilance, Netherlands, Europe, Immunopathology, Skin disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0424126
Code Inist : 002B02U05. Création : 25/01/1999.